ArticleThe journal of obstetrics and gynaecology research2025

Assessment of tissue factor pathway inhibitor 2 (TFPI2) as a novel serum marker for malignant tumors of the ovary before and after treatment: A case-control study.

Yuki Ogawara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.